Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Viviana Garcia-Horton"'
Autor:
Erin Zagadailov, Hanny Al-Samkari, Audra N. Boscoe, Bryan McGee, Sherry Shi, Dendy Macaulay, Lizheng Shi, Viviana Garcia-Horton
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTReal-world studies of pyruvate kinase (PK) deficiency and estimates of mortality are lacking. This retrospective observational study aimed to identify patients with PK deficiency and compare their overall survival (OS) to that of a matched co
Externí odkaz:
https://doaj.org/article/e7058f48d3a6442cba6ae5e2e90410fe
Autor:
Paul Feuerstadt, Jessica R. Allegretti, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L. Bancke, Kerry LaPlante, Kevin W. Garey, Sahil Khanna
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 1, Pp 221-236 (2024)
Abstract Introduction Clostridioides difficile infection (CDI) causes symptoms of varying severity and negatively impacts patients’ health-related quality of life (HRQL). Despite antibiotic treatment, recurrence of CDI (rCDI) is common and imposes
Externí odkaz:
https://doaj.org/article/60bcb17d6e844671925f5267b451bedd
Autor:
Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8005-8017 (2023)
Abstract Backgound Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matc
Externí odkaz:
https://doaj.org/article/25757ea5c0d04b968bda33b211f19236
Autor:
Rajesh Pahwa, Jason Aldred, Aristide Merola, Niodita Gupta, Emi Terasawa, Viviana Garcia-Horton, David R. Steffen, Prasanna L. Kandukuri, Yanjun Bao, Omar Ladhani, Connie H. Yan, Vivek Chaudhari, Stuart H. Isaacson
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 8, Iss , Pp 100181- (2023)
Introduction: Carbidopa/levodopa enteral suspension (CLES) previously demonstrated reduction in total daily OFF from baseline by over 4 hours in advanced Parkinson’s disease patients across 54 weeks. Evidence on CLES’s long-term effectiveness on
Externí odkaz:
https://doaj.org/article/ed5b36cf53c5474baa6f55f091839295
Autor:
Neal Shore, Viviana Garcia-Horton, Emi Terasawa, Rajeev Ayyagari, Jamie Partridge Grossman, Adrianus Reginald Waldeck
Publikováno v:
Future Oncology. 19:385-395
Approval of apalutamide, enzalutamide and darolutamide has transformed the treatment landscape and guideline recommendations for patients with nonmetastatic castration-resistant prostate cancer but now raises the issue of decision-making regarding tr
Autor:
Neal, Shore, Shan, Jiang, Viviana, Garcia-Horton, Emi, Terasawa, David, Steffen, Andi, Chin, Rajeev, Ayyagari, Jamie, Partridge, A Reginald, Waldeck
Publikováno v:
Advances in Therapy. 39:5025-5042
Three novel androgen receptor inhibitors are approved in the USA for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide, enzalutamide, and darolutamide. All three therapies have demonstrated prolonged metastasi
Autor:
Kelly R. Reveles, Min Yang, Viviana Garcia-Horton, Marie Louise Edwards, Amy Guo, Thomas Lodise, Markian Bochan, Glenn Tillotson, Erik R. Dubberke
Publikováno v:
Advances in Therapy.
Autor:
Rajesh Pahwa, Jason Aldred, Niodita Gupta, Emi Terasawa, Viviana Garcia-Horton, David R. Steffen, Prasanna L. Kandukuri, Vivek S. Chaudhari, Yash J. Jalundhwala, Yanjun Bao, Pavnit Kukreja, Stuart H. Isaacson
Publikováno v:
Neurology and Therapy. 11:711-723
A clinical trial in advanced Parkinson's disease (APD) has established the superiority of carbidopa/levodopa enteral suspension (CLES) in reducing total patient "off" time (OFF) and increasing total "on" time without troublesome dyskinesia (ON-woTD)
Autor:
Daniel O, Claassen, Rajeev, Ayyagari, Viviana, Garcia-Horton, Su, Zhang, Jessica, Alexander, Sam, Leo
Publikováno v:
Neurology and Therapy. 11:435-448
Chorea, a common clinical manifestation of Huntington's disease (HD), involves sudden, involuntary movements that interfere with daily functioning and contribute to the morbidity of HD. Tetrabenazine and deutetrabenazine are FDA-approved to treat cho
Autor:
Paul Feuerstadt, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Jonathan Salcedo, Glenn Tillotson, Lindy Bancke, Kevin W. Garey
Publikováno v:
American Journal of Gastroenterology. 117:e604-e605